Literature DB >> 31520149

Promoting stigma coping and empowerment in patients with schizophrenia and depression: results of a cluster-RCT.

Wolfgang Gaebel1,2, Harald Zäske3, Klaus Hesse4, Stefan Klingberg4, Christian Ohmann5, Jürgen Grebe5, Henrike Kolbe5, Andrea Icks6,7, Frank Schneider8,9, Volker Backes8, Claus Wolff-Menzler10, Birgit Guse10, Jürgen Gallinat11, Thomas Bock11, Maria-Christiane Jockers-Scherübl12,13, Timo Krüger12,13, Frank Jessen14, Andreas Bechdolf14, Tilo Kircher15, Carsten Konrad15, Peter Falkai16, Annette Schaub16, Matthias Rudolph17, Volker Köllner18,19, Gerhard Schmid-Ott20, Michael Linden19, Barbara Lieberei19, Monika Stuhlinger21, Sebastian Sommerfeld22, Albrecht Schumacher22, Sabine Krenge22, Stephanie Gereke23, Norbert Mönter23, Alicia Navarro-Urena23, Günter Frosch24, Franz-Josef Kuhlbusch24, Helen Cleveland3, Mathias Riesbeck3,25.   

Abstract

There is a need for interventions supporting patients with mental health conditions in coping with stigma and discrimination. A psycho-educational group therapy module to promote stigma coping and empowerment (STEM) was developed and tested for efficacy in patients with schizophrenia or depression. 30 clinical centers participated in a cluster-randomized clinical trial, representing a broad spectrum of mental health care settings: in-patient (acute treatment, rehabilitation), out-patient, and day-hospitals. As randomized, patients in the intervention group clusters/centers received an illness-specific eight sessions standard psychoeducational group therapy plus three specific sessions on stigma coping and empowerment ('STEM'). In the control group clusters the same standard psychoeducational group therapy was extended to 11 sessions followed by one booster session in both conditions. In total, N = 462 patients were included in the analysis (N = 117 with schizophrenia spectrum disorders, ICD-10 F2x; N = 345 with depression, ICD-10 F31.3-F31.5, F32-F34, and F43.2). Clinical and stigma-related measures were assessed before and directly after treatment, as well as after 6 weeks, 6 months, and 12 months (M12). Primary outcome was improvement in quality of life (QoL) assessed with the WHO-QOL-BREF between pre-assessment and M12 analyzed by mixed models and adjusted for pre-treatment differences. Overall, QoL and secondary outcome measures (symptoms, functioning, compliance, internalized stigma, self-esteem, empowerment) improved significantly, but there was no significant difference between intervention and control group. The short STEM module has proven its practicability as an add-on in different settings in routine mental health care. The overall increase in empowerment in both, schizophrenia and depression, indicates patients' treatment benefit. However, factors contributing to improvement need to be explored.The study has been registered in the following trial registers. ClinicalTrials.gov: https://register.clinicaltrials.gov/ Registration number: NCT01655368. DRKS: https://www.drks.de/drks_web/ Registration number: DRKS00004217.

Entities:  

Keywords:  Cluster-RCT; Depression; Schizophrenia; Stigma; Stigma coping intervention

Mesh:

Year:  2019        PMID: 31520149     DOI: 10.1007/s00406-019-01064-3

Source DB:  PubMed          Journal:  Eur Arch Psychiatry Clin Neurosci        ISSN: 0940-1334            Impact factor:   5.270


  2 in total

1.  Impact of a Virtual Reality-Based Simulation on Empathy and Attitudes Toward Schizophrenia.

Authors:  Antonio J Marques; Paulo Gomes Veloso; Margarida Araújo; Raquel Simões de Almeida; António Correia; Javier Pereira; Cristina Queiros; Rui Pimenta; Anabela S Pereira; Carlos F Silva
Journal:  Front Psychol       Date:  2022-05-04

2.  A 2-year longitudinal study of neuropsychological functioning, psychosocial adjustment and rehospitalisation in schizophrenia and major depression.

Authors:  Schaub Annette; Goerigk Stephan; Kim T Mueser; Hautzinger Martin; Roth Elisabeth; Goldmann Ulrich; Charypar Marketa; Engel Rolf; Möller Hans-Jürgen; Falkai Peter
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2020-04-03       Impact factor: 5.270

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.